上海交通大学学报（医学版）

上海交通大学学报（医学版） ›› 2020, Vol. 40 ›› Issue (1): 128-.doi: 10.3969/j.issn.1674-8115.2020.01.021

• 综述 • 上一篇    下一篇

PD-1/PD-L1通路在三阴性乳腺癌预后预测及治疗中的意义

张凤春1, 2*，张硕渊3*，陈天恩3，徐迎春3   

  1. 1. 上海交通大学医学院附属苏州九龙医院肿瘤科，苏州 215021；2. 上海交通大学医学院附属瑞金医院肿瘤科，上海 200025；3. 上海交通大学医学院附属仁济医院肿瘤科，上海 200127
  • 出版日期:2020-01-28 发布日期:2020-03-05
  • 通讯作者: 徐迎春，电子信箱：xiaoxu2384@163.com。
  • 作者简介:张凤春（1957—），男，主任医师，博士；电子信箱：fczhang2004@163.com；张硕渊（1997—），男，本科生；电子信箱：358302932@qq.com。*为共同第一作者。
  • 基金资助:
    国家自然科学基金（81301858）；江苏省自然科学基金项目（BK20181186）。

Clinical application of PD-1/PD-L1 to prognosis prediction and treatment of triple-negative breast cancer

ZHANG Feng-chun, ZHANG Shuo-yuan, CHEN Tian-en, XU Ying-chun   

  1. 1. Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021, China; 2. Department of Oncology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 3. Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
  • Online:2020-01-28 Published:2020-03-05
  • Supported by:
    National Natural Science Foundation of China (81301858); Natural Science Foundation of Jiangsu Project (BK20181186).

PDF (PC)

421

摘要： 程序性死亡-1（programmed death-1，PD-1）受体及其配体程序性死亡-配体1 (programmed death-ligand 1，PD-L1) 作为T细胞免疫反应过程中的一对协同刺激分子，通过负性调节T淋巴细胞发挥免疫抑制作用。阻断PD-1/PD-L1信号通路已成为肿瘤治疗研究的热点。三阴性乳腺癌（triple-negative breast cancer，TNBC）预后不良、缺乏有效治疗靶点，以PD-1/PD-L1为代表的免疫治疗策略在TNBC中具有广阔的研究和应用前景。其中，抗PD-1和抗PD-L1单克隆抗体的临床研究为转移性TNBC的治疗带来了突破。目前，多个抗PD-1和PD-L1的单克隆抗体及其与其他疗法的联合方案用于治疗TNBC的临床试验正在进行中。该文着重概述目前PD-1/PD-L1在TNBC预后预测和治疗中应用的研究进展，旨在为基础或临床研究提供理论基础。

关键词: 程序性死亡-1/程序性死亡 - 配体1, 三阴性乳腺癌, 治疗, 预后

Abstract:

Programmed death-1 (PD-1) receptor and programmed death-ligand 1 (PD-L1) as a pair of T cell immune response co-stimulatory molecules play a negative role in adoptive immunityinhibiting T lymphocyte function. Blocking the PD-1/PD-L1 signaling pathway has been a hot spot of research and treatment of cancer. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and there is no approved targeted therapy. Immunotherapy representedPD-1/PD-L1 blockers, is getting widely studied due to the medical potential of therapy for TNBC. Thereinto, the clinical researches of the monoclonal antibodies against PD-1 or PD-L1 have brought a promising future for the treatment of metastatic TNBC. Currently, there are several trials with anti-PD-1 or anti-PD-L1 monoclonal antibodies and their combination with other therapies in salvage, neoadjuvant, and adjuvant settings on going. In this article, the authors review the current studies about potential value of PD-1/PD-L1 in prognosis, prediction, and treatment in TNBC, intending to cast insight on future basic and clinical studies.

Key words: programmed death-1/programmed death-ligand 1 (PD-1/PD-L1), triple-negative breast cancer, treatment, prognosis